Utama › Kerdil Pituitari › Texas
Kajian klinikal Kerdil Pituitari di Texas
6 kajian untuk Kerdil Pituitari sedang mencari peserta di lokasi di Texas.
Bandar di Texas
Teks kajian rasmi (Bahasa Inggeris)
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
- Lumos Pharma Investigational Site, Amarillo
- Lumos Pharma Investigational Site, Corpus Christi
- Lumos Pharma Investigational Site, Fort Worth
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 3 hingga 11 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06948214Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
- South Texas Health Care System, San Antonio, TX, San Antonio
Mengambil pesertaFasa 3
Umur 21 hingga 55 · Semua jantina · Dikemas kini 9 Jul 2026 · NCT04867317Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
- Michael E. DeBakey VA Medical Center, Houston
Mengambil pesertaFasa 2
Umur 18 hingga 64 · Semua jantina · Dikemas kini 8 Mei 2026 · NCT05355272A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
- Ascendis Investigational Site, Dallas
- Ascendis Investigational Site, El Paso
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 21 Apr 2026 · NCT05820672A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
- Ascendis Investigational Site, Dallas
- Ascendis Investigational Site, El Paso
Mengambil pesertaKajian pemerhatian
Umur 1 hingga 18 · Semua jantina · Dikemas kini 4 Feb 2026 · NCT05775523Chromosome 18 Clinical Research Center
- University Health Systems Hospital, San Antonio
- University of Texas Health Science Center at San Antonio, San Antonio
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Semua umur · Semua jantina · Dikemas kini 6 Jan 2026 · NCT00227253Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.